Screening for Chlamydia and Gonorrhea: A Draft Recommendation Statement from the Japan Preventive Services Task Force

Mukohara, Kei; Kei Miyazaki; Hideki Mori; Kazuya Honda; Ayako Shibata; Masatsugu Sakata; Masaki Futamura; Yusuke Tsugawa

doi:10.51094/jxiv.5323

##article.authors##

Mukohara, Kei Kurume University
Kei Miyazaki Department of General Medicine & General Internal Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Hideki Mori Department of General Internal Medicine, NHO Nagasaki Medical Center, Omura, Nagasaki, Japan
Kazuya Honda Department of Nursing, Graduate School of Health and Medical Sciences, Junshin Gakuen University (Nurse Practitioner [NP] Course), Fukuoka, Japan
Ayako Shibata Department of Obstetrics & Gynecology, Yodogawa Christian Hospital, Osaka, Japan
Masatsugu Sakata Department of Neurodevelopmental Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Masaki Futamura Department of Pediatrics, NHO Nagoya Medical Center, Nagoya, Japan
Yusuke Tsugawa Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, CA, USA

DOI:

https://doi.org/10.51094/jxiv.5323

キーワード:

chlamydia、 gonorrhea、 screening、 sexually transmitted infections、 Japan

抄録

The US Preventive Services Task Force (USPSTF) recommends screening for chlamydia and gonorrhea in all sexually active women, including pregnant persons, aged 24 years or younger, as well as in women, including pregnant persons, aged 25 years or older who are at increased risk for infection, and concludes with moderate certainty that such screening has a moderate net benefit. However, it remains unclear whether this recommendation is applicable to the Japanese population.

The Japan Preventive Services Task Force (JPPSTF) commissioned an independent literature review of screening for chlamydia and gonorrhea and developed these recommendations.

The JPPSTF concludes with moderate certainty that screening for chlamydia and gonorrhea in sexually active, non-pregnant women aged 10 to 39 years has small net benefit. The JPPSTF concludes with moderate certainty that screening for chlamydia in pregnant persons has moderate net benefit. The JPPSTF concludes with moderate certainty that screening for gonorrhea in pregnant persons has small net benefit. The JPPSTF concludes that the evidence is insufficient and the balance of benefits and harms of screening for chlamydia and gonorrhea in men cannot be determined.

The JPPSTF recommends selectively screening for chlamydia and gonorrhea in sexually active non-pregnant women aged 10 to 39 years in Japan (C recommendation). The JPPSTF recommends screening for chlamydia in all pregnant persons in Japan (B recommendation). The JPPSTF recommends selectively screening for gonorrhea in pregnant persons in Japan (C recommendation). The JPPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men in Japan (I statement).

利益相反に関する開示

Dr. Sakata is employed in the Department of Neurodevelopmental Medicine, Nagoya City University Graduate School of Medicine, which is an endowment department supported by the City of Nagoya. He has received a personal fee from Daiichi-Sankyo outside the s

ダウンロード *前日までの集計結果を表示します

ダウンロード実績データは、公開の翌日以降に作成されます。

引用文献

US Preventive Services Task Force. Grade Definitions. October 2018. [Internet]. [cited 2026 Mar 21]. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions/.

Japan Preventive Services Task Force. JPPSTF Procedure Manual. OSF. Published 2025 May [Internet]. [cited 2026 Mar 21]. Available from: https://osf.io/sr9he/.

Kawado M, Hashimoto S, Ohta A, et al. Estimating nationwide cases of sexually transmitted diseases in 2015 from sentinel surveillance data in Japan. BMC Infect Dis. 2020 Jan 28;20(1):77.

Alexiou ZW, Hoenderboom BM, Hoebe CJPA, et al. Reproductive tract complication risks following Chlamydia trachomatis infections: a long-term prospective cohort study from 2008 to 2022. Lancet Reg Health Eur. 2024 Aug 17;45:101027.

Davies B, Turner KME, Frølund M, et al; Danish Chlamydia Study Group. Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. Lancet Infect Dis. 2016 Sep;16(9):1057-64.

Ryan GM Jr, Abdella TN, McNeeley SG, et al. Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. Am J Obstet Gynecol. 1990 Jan;162(1):34-9.

Tang W, Mao J, Li KT, Walker JS, et al. Pregnancy and fertility-related adverse outcomes associated with Chlamydia trachomatis infection: a global systematic review and meta-analysis. Sex Transm Infect. 2020 Aug;96(5):322-9.

Vallely LM, Egli-Gany D, Wand H, et al. Adverse pregnancy and neonatal outcomes associated with Neisseria gonorrhoeae: systematic review and meta-analysis. Sex Transm Infect. 2021 Mar;97(2):104-111.

Yasuda S, Kyozuka H, Endo Y, et al; Japan Environment, Children’s Study JECS Group. Association of Chlamydia trachomatis infection with pregnancy outcomes among Japanese pregnant women: The Japan environment and children's study. PLoS One. 2022 Nov 29;17(11):e0275573.

Suzuki S, Hoshi SI, Sekizawa A, et al. Current status of Neisseria gonorrhoeae cervicitis in pregnant women in Japan. PLoS One. 2019 Feb 7;14(2):e0211595.

Yamaguchi N, Noda T, Nishioka Y, et al. The Proportion of Coinfections Among Sexually Transmitted Infections in Japan: A Nationwide Claims Database Study. Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf393.

Ministry of Health, Labour and Welfare. Number of reported cases of sexually transmitted diseases (by 5-year age group) [Internet]. Tokyo: MHLW; [cited 2026 Mar 30]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/seikansenshou/houkokusuu.html

Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.

van Veen MG, Koedijk FD, van der Sande MA; Dutch STD centres. STD coinfections in The Netherlands: Specific sexual networks at highest risk. Sex Transm Dis. 2010 Jul;37(7):416-22.

Imai H, Shinohara H, Nakao H, et al. Prevalence and risk factors of asymptomatic chlamydial infection among students in Japan. Int J STD AIDS. 2004 Jun;15(6):408-14.

Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep. 2014 Mar 14;63(RR-02):1-19.

US Food and Drug Administration. FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea. Published May 23, 2019. [Internet] [cited 2026 Mar 22] Available from: https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea

Cantor A, Dana T, Griffin JC, Nelson HD, Atchison C, Winthrop KL, Chou R. Screening for Chlamydial and Gonococcal Infections: A Systematic Review Update for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. Report No.: 21-05275-EF-1.

US Preventive Services Task Force. Screening for Chlamydia and Gonorrhea: Final Research Plan. [Internet] [cited 2026 Jun 13] Available from:

https://www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/chlamydia-and-gonorrhea-screening

Japan Preventive Services Task Force. Screening for Chlamydia and Gonorrehea: Final Research Plan. [Internet] OSF. 2026 [cited 2026 Jun 13]. Available from: https://osf.io/aw7tq/files/5eug6

Miike S, Yamada H, Oda R. Screening for Chlamydia and Gonorrhea: A Draft Update of the Systematic Review Adapted from the USPSTF Review for the Japan Preventive Services Task Force. Jxiv. 2026. doi:10.51094/jxiv.4798. [preprint]

Kranzer K, Simms V, Dauya E, et al. Identifying youth at high risk for sexually transmitted infections in community-based settings using a risk prediction tool: a validation study. BMC Infect Dis. 2021 Dec 8;21(1):1234.

Morris SR, Bristow CC, Wierzbicki MR, et al. Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. Lancet Infect Dis. 2021 May;21(5):668-76.

Vialard F, Anand A, Leung Soo C, et al. Self-sampling strategies (with/without digital innovations) in populations at risk of Chlamydia trachomatis and Neisseria gonorrhoeae: a systematic review and meta-analyses. Sex Transm Infect. 2023 Aug 17;99(6):420-8.

Kondo M, Suzuki A, Futo K, et al. Comparison of strand displacement amplification to polymerase chain reaction for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. Igaku to Yakugaku. 2005;54(5):695-701. Japanese.

Fujiwara M, Kishida Y, Kawamoto Y, et al. Differences in detection rates according to PCR diagnostic criteria for detection of Neisseria gonorrhoeae using endocervical specimens: comparison with culture methods. Jpn J Sex Transm Dis. 2006;17:93-6. Japanese.

Dziva Chikwari C, Dauya E, Simms V, et al. Effect of a community-based intervention for sexually transmitted infections on population-level prevalence among youth in Zimbabwe (STICH): a cluster-randomised trial. Lancet Glob Health. 2025 Jan;13(1):e134-e145.

Pillay J, Wingert A, MacGregor T, et al. Screening for chlamydia and/or gonorrhea in primary health care: systematic reviews on effectiveness and patient preferences. Syst Rev. 2021 Apr 19;10(1):118.

Riddell MA, Vallely LM, Mengi A, et al; WANTAIM study group. Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-resource settings (WANTAIM): a pragmatic cluster randomised crossover trial in Papua New Guinea. Lancet Glob Health. 2024 Apr;12(4):e641-e651.

Mussa A, Wynn A, Ryan R, et al. Effect of antenatal Chlamydia trachomatis and Neisseria gonorrhoeae screening on postdelivery prevalence and vertical transmission in Gaborone, Botswana: findings from an exploratory study. Sex Transm Infect. 2025 Mar 24;101(2):81-7.

Kohlhoff S, Roblin PM, Clement S, et al. Universal Prenatal Screening and Testing and Chlamydia trachomatis Conjunctivitis in Infants. Sex Transm Dis. 2021 Sep 1;48(9):e122-e123.